METASTATIC PROSTATE CANCER

This study is testing two experimental drugs (AZD9574 and AZD2265) together in people with metastatic prostate cancer that has spread beyond the prostate. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 152 adults whose cancer has no…

This study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men wil…

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer…

This study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the …

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose…

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This study tests a new drug called AZD0516, given alone or with other cancer drugs, in people with metastatic prostate cancer that has spread. The main goals are to check safety, find the best dose, and see early signs of tumor control. About 177 participants will take part acros…

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This study looks at men whose prostate cancer has spread to a few spots in the body (oligometastatic). It compares standard radiation and hormone therapy alone versus adding the drug abiraterone for 8-9 months. The goal is to see if the extra drug improves quality of life and del…

This study tests whether taking creatine supplements along with a home-based resistance training program can help men with metastatic prostate cancer maintain muscle mass and reduce fatigue. Two hundred participants will be randomly assigned to receive either creatine or a placeb…

This early-phase study tests whether combining a radioactive drug (177Lu-PSMA-617) with liver-directed procedures (ablation or chemoembolization) is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. The 30 participants must have alrea…

This trial tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to other treatments. The drug is designed to attach to prostate cancer cells and destroy them with radiation. The study aim…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has certain DNA repair gene changes. The trial compares the usual chemo (docetaxel) alone versus docetaxel plus a platinum chemo drug to see if the combination helps patie…

This study for veterans with prostate cancer that has returned in a few spots (oligorecurrence) compares standard systemic therapy alone versus standard therapy plus PET-directed local treatment using surgery or radiation. The goal is to see if adding local therapy delays the can…

This study follows 170 men in China with metastatic prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how much their PSA levels drop, how long the cancer stays controlled, and their quality of life during and up to one year after tre…

This study tests whether a 16-week supervised exercise program (circuit training with resistance, functional, and aerobic exercises) can improve frailty and muscle loss in 80 men with metastatic prostate cancer who are on hormone therapy. Participants must be pre-frail or frail. …

This phase II study tests two experimental drugs, HS-20093 and SHR2554, combined with standard hormone therapies in 218 men with metastatic prostate cancer. The goal is to see if these combos are safe and can lower PSA levels or slow the cancer's spread. Participants must have ad…

This study tests a new treatment called AZD0754 for men with metastatic prostate cancer that has spread and is no longer responding to hormone therapy. AZD0754 is a type of immunotherapy where a patient's own immune cells are modified in a lab to better recognize and attack cance…

This study tests whether adding dexamethasone or metronidazole to standard therapy can restore sensitivity to abiraterone in men with metastatic prostate cancer that has stopped responding. About 58 men whose cancer progressed on abiraterone will receive either dexamethasone or d…

This study tests whether adding prostate cryoablation (freezing the tumor) and a low-dose chemotherapy drug (cyclophosphamide) to standard hormone therapy can delay cancer progression in men with newly diagnosed metastatic prostate cancer. About 104 men aged 18-80 will receive th…

This study tests whether a personalized diet and exercise program is practical for 30 men with metastatic prostate cancer who are already receiving hormone therapy. The goal is to see if patients can stick with the program and if it helps control their cancer. The study does not …

This study tests a new drug called HRS-1167 combined with two standard medications (abiraterone and prednisone) in men with metastatic prostate cancer. The goal is to see if the combination is safe, tolerable, and effective. About 66 participants will be enrolled across multiple …

This study tests a new imaging approach for people with advanced breast or prostate cancer. It uses two radioactive tracers to find tumors that have a specific protein (GRPR). The goal is to see if this method is safe and can help doctors see where the cancer is in the body. Abou…

This early study tests whether a special PET scan using 18F-fluciclovine can find prostate cancer that doesn't show up well on standard PSMA scans. The study will include 30 men with advanced prostate cancer that either has low PSMA levels or has changed into a more aggressive ne…

This study tests a software tool called TRAQinform Theranostics that analyzes PET/CT scans to help doctors decide on treatment for metastatic prostate cancer. Researchers will see if having this extra information changes the treatment plan. The study involves 32 patients starting…

This study tests whether two home-based exercise programs—walking or high-intensity cycling—can improve fitness and reduce fatigue in men with metastatic prostate cancer who are starting hormone therapy. Twenty-four participants will exercise at home for 12 weeks, with remote mon…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study is collecting prostate cancer tissue from 16 men with metastatic prostate cancer to analyze the tumor microenvironment—the cells and structures around the tumor. Researchers will use advanced genetic and molecular tests to understand how the immune system interacts wit…

This study compares three different blood tests (CellSearch, Parsortix, and SmartCatch) to see which one best detects circulating tumor cells in patients with metastatic breast or prostate cancer. Researchers will take blood samples from 54 patients before they start a new treatm…

This pilot study is testing whether taking endocrine therapy in the morning or evening makes a difference for people with metastatic breast or prostate cancer. Fifty participants will be randomly assigned to take their medication either within an hour of waking or within an hour …

This study looks at whether having a pharmacist review all medications (including those from other doctors) can improve safety for cancer patients receiving targeted radionuclide therapy. The study will include 600 adults with thyroid cancer, metastatic prostate cancer, or neuroe…

This study aims to increase the use of next-generation sequencing (NGS) testing in men with metastatic prostate cancer at Johns Hopkins. Researchers will test ways to overcome barriers for both doctors and patients. About 256 men newly diagnosed with metastatic prostate cancer wi…

This study aims to find new markers in urine that can tell the difference between aggressive prostate cancer and slow-growing types that don't need treatment. Researchers will analyze urine samples from 2000 men before and after they take a multi-carotenoid supplement for 8 weeks…

This study gathers information from medical records of 534 people with metastatic prostate cancer worldwide. It looks at how well different treatments work in everyday practice, including hormone therapy, a radioactive drug called Lutetium-177, and PARP inhibitors. The goal is to…